Today: 15 May 2026
Lumentum stock slips into 2026 as New Year’s Day shuts U.S. markets; earnings next in focus
1 January 2026
1 min read

Lumentum stock slips into 2026 as New Year’s Day shuts U.S. markets; earnings next in focus

NEW YORK, January 1, 2026, 4:38 PM ET — Market closed

  • Lumentum ended the last session of 2025 down 0.7% at $368.59.
  • The stock’s roughly 339% rise over the past year has pushed expectations higher heading into February results.
  • U.S. indexes finished 2025 lower on Dec. 31, with optical peers also retreating.

Lumentum Holdings Inc. shares were unchanged on Thursday with U.S. stock markets shut for New Year’s Day, after the optical components maker closed down 0.7% at $368.59 in the final session of 2025.

That year-end dip comes with the stock still up about 339% over the past 12 months through Dec. 31, leaving little room for disappointment as investors reset positioning for 2026.

Wall Street ended 2025’s final session lower, with the S&P 500 down 0.74% and the Nasdaq off 0.76%, as traders took profits after an AI-fueled run that pushed major indexes to record highs during the year.

Other optics and networking names also eased: Coherent fell 1.2%, Ciena dropped 1.9% and Applied Optoelectronics slid 3.2% on the day, according to market data.

Lumentum designs optical and photonic products used in cloud and communications networks and laser applications, with a Cloud & Networking segment that includes products for AI/ML and data-center interconnect uses, Reuters company information shows.

Investors have been rotating out of crowded growth trades into year-end, with volatility amplified by lighter holiday trading. “It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off,” Mark Hackett, chief market strategist at Nationwide, said this week. Reuters

Lumentum traded between $367 and $379.12 in Wednesday’s regular session on volume of about 1.6 million shares, and remains below its 52-week high of $401.60, market data show.

Macro backdrops are also in play for high-multiple tech. The Federal Reserve’s next policy meeting is scheduled for Jan. 27-28, and investors have been leaning toward a hold on rates, Reuters reported.

Company-specific attention is on the next earnings report, with Wall Street calendars estimating results around Feb. 5 after the close. Investors will be listening for updates tied to cloud-networking demand and margins.

Before next session: U.S. stock markets are scheduled to reopen on Friday, Jan. 2, after the New Year’s Day holiday closure.

Before next session: The next major U.S. macro catalysts land next week, led by the December employment report on Jan. 9 and the December CPI report on Jan. 13, the Bureau of Labor Statistics schedule shows.

Before next session: For Lumentum, traders will be watching whether the stock can hold above Wednesday’s $367 low, with the prior 52-week high near $402 the obvious upside reference point if risk appetite returns.

Stock Market Today

  • OceanaGold Shares Seen Surging 81% on U.S. Gold Mine Plans
    May 15, 2026, 5:45 PM EDT. OceanaGold Corp. (TSX: OGC) is poised for an 81% share price rise following exploration updates at its Haile gold mine in South Carolina. National Bank and RBC Capital Markets set price targets near $76-$78, well above Friday's close of $43.07. The company plans to shift from open-pit to underground mining, fueling expected increases in production and EBITDA (earnings before interest, taxes, depreciation, and amortization). TD Cowen analysts also foresee support for future operations with a $56 target. OceanaGold's 12-month consensus target stands at about $64.95 from 11 analysts, underpinning investor interest in this major U.S. asset.

Latest articles

Tonix Pharma Shares Jump on Antibody Data, 2027 Lyme Trial Eyed

Tonix Pharma Shares Jump on Antibody Data, 2027 Lyme Trial Eyed

15 May 2026
Tonix Pharmaceuticals filed new Phase 1 modeling data showing its experimental Lyme disease antibody, TNX-4800, could maintain serum levels above a proposed protective threshold for six months with a two-dose regimen. Shares rose $1.65 to $15.74 Friday. The company plans a Phase 2 trial in 2027, pending FDA agreement. No Lyme vaccine is currently available in the U.S.
AXT delays annual meeting to June after AI-driven stock jump

AXT delays annual meeting to June after AI-driven stock jump

15 May 2026
AXT adjourned its 2026 annual meeting after failing to reach a quorum, rescheduling for June 4. The company seeks shareholder approval to raise authorized common shares to 120 million from 70 million. Shares closed at $123.78, up 7.65%, after a volatile session. China’s export controls on indium phosphide remain a key risk for AXT’s business.
Hyperscale Data Climbs on $5 Million Tender Offer; Spotlight Turns to 10-Q

Hyperscale Data Climbs on $5 Million Tender Offer; Spotlight Turns to 10-Q

15 May 2026
Hyperscale Data plans a tender offer to buy up to $5 million of Class A shares at $0.21 each, above the last GPUS trade at $0.146. The company reported a preliminary first-quarter net loss of about $30 million on revenue of $44 million and filed a late notice for its Form 10-Q. The offer is pending board and regulatory approval.
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Microsoft stock forecast for 2026: Wedbush puts $625 target on MSFT as “inflection year” looms
Next Story

Microsoft stock forecast for 2026: Wedbush puts $625 target on MSFT as “inflection year” looms

Go toTop